First Physicians Capital Group, Inc. - FORM 10-Q

First Physicians Capital Group, Inc. - FORM 10-Q - April 4, 2014

Attached files

Attached files

First Physicians Capital Group, Inc. Reports

Attached files

First Physicians Capital Group, Inc. Reports

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

file	filename
EXCEL - IDEA: XBRL DOCUMENT - First Physicians Capital Group, Inc.	Financial_Report.xls
EX-31.1 - EX-31.1 - First Physicians Capital Group, Inc.	d680907dex311.htm
EX-32.1 - EX-32.1 - First Physicians Capital Group, Inc.	d680907dex321.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

¨	TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 000-30326

FIRST PHYSICIANS CAPITAL GROUP, INC.

(Exact Name of Registrant as Specified in Its Charter)


DELAWARE		77-0557617
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

433 North Camden Drive #810 Beverly Hills, California		90210
(Address of principal executive offices)		(Zip Code)

(310) 860-2501

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ¨ Yes x No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes x No


Number of shares of common stock outstanding as of March 28, 2014			23,909,507

EXPLANATORY NOTE

The last periodic report of First Physicians Capital Group, Inc. (the “Registrant”) filed with the Securities and Exchange Commission was the Form 10-Q for the Fiscal Quarter Ended December 31, 2010, filed February 22, 2011. In order to become current with all required quarterly and annual reports under the Section 13(a) of the Securities Exchange Act of 1934, the Registrant is filing this Form 10-Q for the Fiscal Quarter Ended June 30, 2013 concurrently with Form 10-Q’s for the Fiscal Quarters Ended March 31, 2011, June 30, 2011, December 31, 2011, March 31, 2012, June 30, 2012, December 31, 2012, March 31, 2013 and December 31, 2013, and Form 10-K’s for the Fiscal Years Ended September 30, 2011, September 30, 2012 and September 30, 2013.

TABLE OF CONTENTS


	Page

PART I		1
FINANCIAL INFORMATION		1
Item 1. FINANCIAL STATEMENTS		1
Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		12
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		14
Item 4. CONTROLS AND PROCEDURES		15
PART II OTHER INFORMATION		16
Item 1. LEGAL PROCEEDINGS		16
Item 1A. RISK FACTORS		16
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS		16
Item 3. DEFAULTS UPON SENIOR SECURITIES		16
Item 4. MINE SAFETY DISCLOSURES		16
Item 5. OTHER INFORMATION		16
Item 6. EXHIBITS		16
SIGNATURES		17
EXHIBIT INDEX		18

PART I

FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

FIRST PHYSICIANS CAPITAL GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except shares and per share data)


	June 30, 2013			September 30, 2012
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	188		$	1,389
Accounts receivable, net of allowance for uncollectible accounts		12,554			9,604
Prepaid expenses		233			51
Other current assets		13			7
Assets of discontinued operations		—			8

Total current assets		12,988			11,059
Property and equipment, net		4			11
Notes receivable		22,343			22,343
Other assets		254			268

Total assets	$	35,589		$	33,681

LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	806		$	884
Accrued expenses		2,739			2,176
Income taxes payable		212			212
Current maturities of long term debt		1,750			5,041
Liabilities of discontinued operations		557			572

Total current liabilities		6,064			8,885
Long term debt, net of current portion		5,881			6,161
Deferred gain		15,547			15,698

Total liabilities		27,492			30,744
Commitments and contingencies
Non-redeemable preferred stock:
Preferred stock Series 1-A ($0.01 par value, 2,802,000 shares authorized; 67,600 shares issued and outstanding as of June 30, 2013 and September 30, 2012)		166			166
Preferred stock Series 2-A ($0.01 par value, 1,672,328 shares authorized; 3,900 shares issued and outstanding as of June 30, 2013 and September 30, 2012)		25			25

Total non-redeemable preferred stock		191			191
Redeemable preferred stock:
Preferred stock Series 5-A ($0.01 par value, 5,000,000 shares authorized; 9,000 shares issued and outstanding as of June 30, 2013 and September 30, 2012)		7,832			7,832
Preferred stock Series 6-A ($0.01 par value, 5,000 shares authorized; 4,875 shares issued and outstanding as of June 30, 2013 and September 30, 2012)		4,381			4,381

Total redeemable preferred stock		12,213			12,213
Stockholders’ deficit:
Common stock ($0.01 par value, 100,000,000 shares authorized; 15,049,507 shares issued and outstanding as of June 30, 2013 and September 30, 2012)		153			153
Additional paid-in-capital		81,574			81,004
Accumulated deficit		(85,930	)		(90,520	)
Treasury stock, at cost (149,744 shares as of June 30, 2013 and September 30, 2012)		(104	)		(104	)

Total stockholders’ deficit		(4,307	)		(9,467	)

Total liabilities, preferred stock and stockholders’ deficit	$	35,589		$	33,681

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FIRST PHYSICIANS CAPITAL GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands except share and per share data)

(Unaudited)


	Three months ended
	June 30, 2013			June 30, 2012
Net revenue from services	$	4,763		$	4,306
Cost and expenses:
Selling, general and administrative expenses		3,188			2,621
Depreciation and amortization		2			6

Total costs and expenses		3,190			2,627

Operating income		1,573			1,679
Other expense:
Interest expense		(148	)		(359	)

Total other expense		(148	)		(359	)

Net income from continuing operations	$	1,425		$	1,320

Net income from discontinued operations, net of income taxes (including net gain from disposal of assets of $50 and $50, respectively. See Note 2. “Discontinued Operations”)		50			50

Net income	$	1,475		$	1,370

Basic earnings per share of common stock:
Continuing operations	$	0.09		$	0.09
Discontinued operations		0.01			0.00

Total basic earnings per share of common stock	$	0.10		$	0.09

Diluted earnings per share of common stock:
Continuing operations	$	0.02		$	0.02
Discontinued operations		0.00			0.00

Total diluted earnings per share of common stock	$	0.02		$	0.02

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FIRST PHYSICIANS CAPITAL GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands except share and per share data)

(Unaudited)


	Nine months ended
	June 30, 2013			June 30, 2012
Net revenue from services	$	14,402		$	12,106
Cost and expenses:
Selling, general and administrative expenses		9,290			7,955
Depreciation and amortization		7			16

Total costs and expenses		9,297			7,971

Operating income		5,105			4,135
Other income (expense):
Interest expense		(666	)		(854	)
Gain on retirement of note payable		—			1,447

Total other income (expense)		(666	)		593

Net income from continuing operations	$	4,439		$	4,728

Net income from discontinued operations, net of income taxes (including net gain from disposal of assets of $151 and $151, respectively. See Note 2. “Discontinued Operations”)		151			154

Net income	$	4,590		$	4,882

Basic earnings per share of common stock:
Continuing operations	$	0.29		$	0.31
Discontinued operations		0.01			0.01

Total basic earnings per share of common stock	$	0.30		$	0.32

Diluted earnings per share of common stock:
Continuing operations	$	0.07		$	0.08
Discontinued operations		0.01			0.00

Total diluted earnings per share of common stock	$	0.08		$	0.08

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FIRST PHYSICIANS CAPITAL GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)


	Nine months ended
	June 30, 2013			June 30, 2012
Cash flows from operating activities:
Net income	$	4,590		$	4,882
Net income from discontinued operations		151			154

Net income from continuing operations		4,439			4,728
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on retirement of note payable		—			(1,447	)
Depreciation and amortization		7			16
Amortization of stock-based compensation		570			581
Bad debt provision		7,335			3,772
Changes in working capital components:
Accounts receivable		(10,285	)		(6,702	)
Prepaid expenses		(182	)		(44	)
Other assets		8			49
Accounts payable		(78	)		115
Accrued expenses		563			(318	)

Net cash provided by operating activities		2,377			750
Net cash provided by (used in) discontinued operations’ operating activities		(7	)		12

Net cash provided by operating activities		2,370			762
Cash flows from financing activities:
Proceeds from long term debt		—			2,089
Payments on long term debt		(3,571	)		(265	)

Net cash provided by (used in) financing activities		(3,571	)		1,824

Net increase (decrease) in cash and cash equivalents		(1,201	)		2,586
Cash and cash equivalents at beginning of year		1,389			1,001

Cash and cash equivalents at end of quarter	$	188		$	3,587

Supplemental cash flow information:
Cash paid for interest	$	422		$	496
Cash paid for taxes		—			—
Non-cash transactions:
Note receivable given as consideration for payment of note payable	$	—		$	2,150
Notes payable extinguished through assignment of notes receivable	$	—		$	1,500

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

FIRST PHYSICIANS CAPITAL GROUP, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of First Physicians Capital Group, Inc., f/k/a Tri-Isthmus Group, Inc., a Delaware corporation (the “Company,” “we,” “us,” or “our,” depending on the context), as of June 30, 2013 and September 30, 2012 and for the three and nine month periods ended June 30, 2013 and June 30, 2012, have been prepared on substantially the same basis as our annual consolidated financial statements and should be read in conjunction with our Annual Report on Form 10-K (the “Form 10-K”), filed with the United States Securities and Exchange Commission (the “SEC”) on April 4, 2014, and any amendments thereto, for the Fiscal Year Ended September 30, 2012 (the “Fiscal Year Ended September 30, 2012”). In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments of a normal recurring nature considered necessary to present fairly the financial information included herein.

The consolidated financial statements include our accounts and the accounts of our subsidiaries. All significant inter-company balances and transactions have been eliminated.

The results as of September 30, 2012 have been derived from our audited consolidated financial statements for the fiscal year ended as of such date.

The unaudited consolidated results for interim periods are not necessarily indicative of expected results for the full fiscal year.

Future Funding

We have an accumulated deficit of approximately $85.9 million as of June 30, 2013. This deficit has been funded primarily through preferred stock and common stock, promissory notes and cash generated from operations.

At June 30, 2013, we had current liabilities of $6.1 million and current assets of $13.0 million.

Critical Accounting Policies

For critical accounting policies affecting us, see Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report on Form 10-K for the Fiscal Year Ended September 30, 2012. Critical accounting policies affecting us have not changed materially since September 30, 2012.

Fair Value of Financial Instruments

Carrying amounts of certain of our financial instruments including accounts receivable, accounts payable and accrued expenses approximate fair value due to their short maturities. Carrying value of notes receivable and long-term debt approximate fair values as they bear market rates of interest. None of our financial instruments are held for trading purposes.

Revenue Recognition

The Company has contracted billing rates for its management services which it bills as gross revenue as services are delivered. Gross billed revenues are then reduced by the Company’s estimate of allowances based on expected collections, which includes the provision for doubtful accounts, to arrive at net revenues. Net revenues may not represent amounts ultimately collected. The Company adjusts current period revenue for differences in estimated revenue recorded in prior periods and actual cash collections.

FIRST PHYSICIANS CAPITAL GROUP, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

The following table shows gross revenues and allowances for the three and nine months ended June 30, 2013 and 2012 (in thousands):


	Three months ended						Nine months ended
	June 30, 2013			June 30, 2012			June 30, 2013			June 30, 2012
Revenue from services	$	7,194		$	5,654		$	21,737		$	15,878
Allowances		(2,431	)		(1,348	)		(7,335	)		(3,772	)

Net revenue	$	4,763		$	4,306		$	14,402		$	12,106

Allowances percentage		34	%		24	%		34	%		24	%

The Company computes its estimate of bad debt by taking into account collections received, for the services performed and also estimating amounts collectible for the services performed within the last twelve months.

2. Discontinued Operations

As of June 30, 2013 and 2012, the operating assets of RHA Tishomingo, RHA Anadarko, RHA Stroud, SPMC, Del Mar, Point Loma, and SPA, have been recorded as assets held for sale and the liabilities as liabilities of operations held for sale. We have reclassified the results of operations of RHA Tishomingo, RHA Anadarko, RHA Stroud, SPMC, Del Mar, Point Loma, and SPA for all periods presented, to discontinued operations.

The results of discontinued operations for the three and nine months ended June 30, 2013 and 2012 are as follows (in thousands):


	Three Months ended				Nine Months ended
	June 30, 2013		June 30, 2012		June 30, 2013		June 30, 2012
Net revenue from services	$	—	$	—	$	—	$	5
Costs and expenses:
Selling, general and administrative expenses		—		—		—		2

Total costs and expenses		—		—		—		2
Income before income taxes		—		—		—		3
Taxation		—		—		—		—

Net income from discontinued operations	$	—	$	—	$	—	$	3

3. Net Income Per Share


	Three months ended (in thousands)				Nine months ended (in thousands)
	June 30, 2013		June 30, 2012		June 30, 2013		June 30, 2012
Numerator for basic and diluted income per share:
Net income attributable to continuing operations	$	1,425	$	1,320	$	4,439	$	4,728
Net income attributable to discontinued operations		50		50		151		154
Denominator for basic earnings per share — weighted average shares		15,049,507		15,049,507		15,049,507		15,049,507
Numerator for diluted earnings per share:
Net income attributable to continuing operations		1,459		1,373		4,541		4,887
Net income attributable to discontinued operations		50		50		151		154
Denominator for diluted earnings per share — weighted average shares		61,644,872		62,844,872		61,644,872		62,844,872
Basic earnings per share of common stock:
Continuing operations	$	0.09	$	0.09	$	0.29	$	0.31
Discontinued operations		0.01		0.00		0.01		0.01

Total basic earnings per share of common stock	$	0.10	$	0.09	$	0.30	$	0.32

Diluted earnings per share of common stock:
Continuing operations	$	0.02	$	0.02	$	0.07	$	0.08
Discontinued operations		0.00		0.00		0.01		0.00

Total diluted earnings per share of common stock	$	0.02	$	0.02	$	0.08	$	0.08

For the three and nine month periods ended June 30, 2013 and 2012, the Company had stock options outstanding to purchase 6,760,000 common shares and warrants outstanding to purchase 360,000 and 846,250 common shares respectively, had strike prices above market value and are considered “out-of-the-money.” As a result they were excluded from the computation of diluted net income per share.

FIRST PHYSICIANS CAPITAL GROUP, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

For the three and nine month periods ended June 30, 2013 and 2012, the following potential common shares outstanding are included in the computation of diluted net income per share: 67,600 Series 1-A Convertible Preferred Stock convertible into 33,493 common shares, 3,900 Series 2-A Convertible Preferred Stock convertible into 1,872 common shares, 9,000 Series 5-A Convertible Preferred Stock convertible into 28,800,000 common shares, 4,875 Series 6-A Convertible Preferred Stock convertible into 15,600,000 common shares. For the three and nine month periods ended June 30, 2013 and 2012, $1,350,000 and $2,100,000 respectively, of 2009 Bridge Financing convertible into 2,160,000 and 3,360,000 common shares respectively was included.

For the three and nine month periods ended June 30, 2013, interest expense of $34,000 and $102,000, respectively, related to the convertible debt was added back to net income attributable to continuing operations for the computation of diluted net income per share.

For the three and nine month periods ended June 30, 2012, interest expense of $53,000 and $159,000, respectively, related to the convertible debt was added back to net income attributable to continuing operations for the computation of diluted net income per share.

4. Accounts Receivable

Accounts receivable consisted of the following (in thousands):


	June 30, 2013			September 30, 2012
Gross accounts receivable	$	29,193		$	18,908
Reserves for bad debt		(16,639	)		(9,304	)

Accounts receivable, net	$	12,554		$	9,604

5. Long-term Debt

The 2011 Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the Fiscal Year Ended September 30, 2013, in installments of $420,000 and $1,614,000, respectively. The 2012 Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the Fiscal Year Ended September 30, 2013, in installments of $225,000 and $1,054,000, respectively.

Long-term debt consists of the following (in thousands):


	June 30, 2013			September 30, 2012
Note payable secured by real estate, $27,513 payable monthly, including interest based on Wall Street Journal prime plus 2% adjusted quarterly, floor of 7%, rate is currently 7%, matures November 2028	$	3,086		$	3,170
Note payable secured by real estate, $34,144 payable monthly, including interest based on Wall Street Journal prime plus 2% adjusted quarterly, floor of 7%, rate is currently 7%, matures November 2028		2,873			2,995
Bridge notes payable, 10% interest, matures on or before June 2014		1,350			4,663
Note payable, 9% interest per annum and matures in February 2016		222			274
Note payable, 10% interest per annum, matures September 2014		100			100

Total		7,631			11,202

Less current maturities of long term debt		(1,750	)		(5,041	)

Total long term debt	$	5,881		$	6,161

FIRST PHYSICIANS CAPITAL GROUP, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

The following chart shows scheduled principal payments due on long-term debt as of June 30, 2013 for the next five years and thereafter (in thousands):


June 30,	Payments
2014	$	1,750
2015		532
2016		458
2017		408
2018		443
Thereafter		4,040

Total	$	7,631

6. Warrants

Outstanding exercisable warrants consisted of the following as of June 30, 2013:

Description

Remaining
Life

Exercise
Price

Warrants

June 8, 2009 Preferred Stock Series 6-A warrants issued to investor

9 months

0.50

210,000

June 10, 2009 warrants issued to Medical Advisory Board

9 months

0.63

150,000

360,000

A summary of our stock warrant activity and related information at June 30, 2013 and September 30, 2012 is as follows:


	Number of Shares of Common Stock						Weighted-Average Exercise Price Per Share
	Nine months Ended June 30, 2013			Fiscal year Ended September 30, 2012			Nine months Ended June 30, 2013		Fiscal year Ended September 30, 2012
Warrants outstanding at beginning of the period		796,250			4,731,513		$	0.52	$	0.58
Issued		—			—			—		—
Exercised		—			—			—		—
Cancelled or expired		(436,250	)		(3,935,263	)	$	0.50	$	0.60

Warrants outstanding at end of the period		360,000			796,250		$	0.55	$	0.52

FIRST PHYSICIANS CAPITAL GROUP, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

7. Stock Options

The following summarizes activities under the stock option plans:


	Number of Options					Weighted-Average Exercise Price Per Share
	Nine months ended June 30, 2013		Fiscal year ended September 30, 2012			Nine months ended June 30, 2013		Fiscal year ended September 30, 2012
Options outstanding at beginning of the period		6,760,000		7,260,000		$	0.61	$	0.61
Granted
— at above fair market value		—		—			—		—
— at fair market value		—		—			—		—
— at below fair market value		—		—			—		—
Exercised		—		—			—		—
Cancelled		—		—			—		—
Forfeited		—		(500,000	)		—		0.61

Options outstanding at end of the period		6,760,000		6,760,000		$	0.61	$	0.61

Options vested/exercisable at end of the period		6,730,000		5,450,000		$	0.61	$	0.61

The following summarizes information for stock options outstanding as of June 30, 2013:


Exercise price	Number of options		Weighted-average exercise price		Weighted-average remaining contractual life
$0.40		360,000	$	0.40		0.50
$0.63		6,400,000	$	0.63		2.05

8. Subsequent Events

2013 Bridge Financing

Beginning in November 2013, we entered into a staggered bridge financing transaction (the “2013 Bridge Financing”) whereby we entered into four promissory notes, with interest of 10% per annum, in the aggregate principal amount of $650,000 (the “2013 Bridge Notes”), with four investors, each note maturing June 30, 2014. The 2013 Bridge Loans funded as follows; $450,000 and $200,000 in November 2013 and January 2014, respectively. Three of the investors, SMP Investments I, LLC (SMP), Anthony J. Ciabottoni, and William Houlihan each hold a 10% or greater voting interest and are considered related parties. The fourth investor, Blue Ridge Investments, LLC is wholly owned by Richardson Sells, a member of the Board, and is therefore also considered a related party. The four lenders contributed $300,000, $125,000, $125,000, and $100,000, respectively.

Bridge Note Extensions

In January 2014, each 2011 Bridge Lender agreed to extend the maturity date(s) of their respective Notes with the same terms and conditions contained in the originally executed Notes and related extensions until June 2014. Also in January 2014, each 2009 Bridge Lender agreed to extend the maturity date(s) of their respective Notes with the same terms and conditions contained in the originally executed Notes and related extensions until June of 2014. Three of the Bridge Lenders, SMP, Anthony Ciabattoni, and William A. Houlihan each hold a 10% or greater voting interest and are considered related parties to this transaction.

In addition, as part of the 2009 Bridge Notes extensions, in January 2014 the Company issued “penny” warrants to SMP for the purchase of up to 8,500,000 shares of Common Stock at an initial exercise price of $0.01 per share and exercisable for a period of five years from the date of issuance. SMP was one of the original 2009 Bridge Financing lenders. SMP holds a 10% or greater voting interest and is considered a related party. In March 2014, SMP exercised its warrant to purchase 8,500,000 shares of common stock for an aggregate purchase price of $85,000. The $85,000 proceeds were received by the company in Fiscal Year 2013, and were recorded as a liability until such time as the Company was able to accept the warrants.

FIRST PHYSICIANS CAPITAL GROUP, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

Bridge Notes Payments

The 2011 Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the Fiscal Year Ended September 31, 2013, in installments of $420,000 and $1,614,000, respectively. The 2012 Bridge Notes were paid in full, less accumulated interest, in the second and third quarters of the Fiscal Year Ended September 31, 2013, in installments of $225,000 and $1,054,000, respectively. Of the total repayments, $759,000, $380,000 and $420,000 went to SMP, Anthony J. Ciabattoni, and William Houlihan, respectively, each of whom hold a 10% or greater voting interest and are considered related parties to this transaction.

Series 5-A and 6-A Convertible Preferred Stock Waiver

In February 2014, a majority of the Series 5-A Convertible Preferred Stock and Series 6-A Convertible Preferred Stock holders consented to waive their rights to demand registration. As a result of the majority consent, demand registration rights for all of the stockholders of the two classes of stock were waived.

Warrant Exercise

In March 2014, we accepted two warrant exercises in the amount of 150,000 and 210,000 shares of Common Stock, at an exercise price of $0.625 and $0.50 per share respectively, for an aggregate purchase price of $198,000 from two investors. The $198,000 proceeds had been received by the company in Fiscal Year 2011, and were recorded as a liability until such time as the Company was able to accept the warrants.

Warrant Issuance

The 2011 Bridge Financing had attached warrants to purchase an aggregate of 2,278,079 shares of our Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. These warrants were issued January 1, 2014. Three of the 2011 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold a 10% or greater voting interest and are considered related parties to this transaction and received in aggregate 1,746,080 of the warrants.

The 2012 Bridge Financing had attached warrants to purchase an aggregate of 4,092,800 shares of our Common Stock with an exercise price of $0.3125, maturing five years from date of issuance. These warrants were issued January 1, 2014. The 2012 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan each hold a 10% or greater voting interest and are considered related parties to this transaction.

Series 7-A Convertible Preferred Stock

On December 5, 2013, the Company filed a Certificate of Designation of Rights and Preferences of Series 7-A Convertible Preferred Stock authorizing the issuance of up to 7,000 Series 7-A Convertible Preferred Stock (see Exhibit 3.11). As part of the consideration for entering into the 2011 Bridge Financing, all of the 2011 Bridge Lenders were granted the option to convert their current holdings if any, of Series 5-A Preferred Convertible Stock, 6-A Preferred Convertible Stock and Common Stock (collectively the “Exchanged Securities”), into Series 7-A Convertible Preferred Stock. Upon election to convert, each lender would receive the number of Series 7-A Convertible Preferred Stock equal to the initial consideration paid for their Exchanged Securities divided by $1,000. In connection with the conversion, each 2011 Bridge Lender shall receive warrants to purchase a number of shares of Common Stock of the Company in an amount equal to 1,120 multiplied by the aggregate number of shares of Series 7-A Preferred issued. Such issued warrants shall have an exercise price of $0.3125, and shall expire five years from date of issuance. The Company has received notification from all the 2011 Bridge Lenders of their intent to convert, as appropriate, their holdings of Exchanged Securities to Series 7-A Convertible Preferred Stock, which will result in the issuance of an aggregate of 5,998 Series 7-A Preferred Stock and warrants to purchase 6,717,760 shares of Common Stock. Three of the 2011 Bridge Lenders, SMP, Anthony J. Ciabattoni, and William A. Houlihan, each hold a 10% or greater voting interest and will be considered related parties to this transaction.

FIRST PHYSICIANS CAPITAL GROUP, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

Litigation

In June 2011, the Company vacated office space in Oklahoma City, Oklahoma prior to the expiration of the lease, at which time the landlord proceeded with litigation to collect outstanding lease payments. In December 2013, both parties entered into a settlement agreement under which the Company agreed to make a one-time payment of $65,000 in full satisfaction of all amounts due under the lease terms.

Change in Management

Effective November 18, 2013, David Hirschhorn resigned (i) as Chief Executive Officer, Chairman of the Board of Directors (the “Board”) and as a member of the Board of First Physicians Capital Group, Inc., a Delaware corporation (the “Registrant”) and (ii) from any and all other positions and in all other capacities in which he served as an officer or director of the Registrant or any of the Registrant’s subsidiaries. Mr. Hirschhorn had no disagreements with the Registrant on any matter related to the Registrant’s operations, policies or practices.

On November 21, 2013, the Board appointed Sean J. Kirrane to the position of Chief Executive Officer and Chief Financial Officer of the Registrant to serve until his successor is duly appointed and qualified or until his earlier resignation or removal. Mr. Kirrane has no family relationship with any officer or director of the Registrant or any of its subsidiaries.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this “Form 10-Q”).

FORWARD LOOKING STATEMENTS

The discussion in this Form 10-Q contains forward-looking statements that may be subject to protection under the Private Securities Litigation Reform Act of 1995 and such statements should not be unduly relied upon. Forward-looking statements can be identified by the use of words such as “may,” “will,” “could,” “should,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans” and variations thereof or of similar expressions. All forward-looking statements included in this Form 10-Q are based on information available to us on the date hereof. We assume no obligation to update any such forward-looking statements. Our actual results in future periods could differ materially from those indicated in such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to:

•

our ability to obtain ongoing financing, manage our cash resources, control expenses and continue as a going concern;

•

impact of our indebtedness on our ability to invest in the ongoing needs and growth of our business;

•

significant past operating losses, potential future losses and limited ongoing revenue;

•

changes in government regulation, particularly healthcare laws;

•

possession of significant voting control over us by the holders of our Series 5-A Preferred Stock and Series 6-A Convertible Preferred Stock;

•

increased competition in the industry, geography and the segments in which we compete;

•

our ability to attract and retain employees and key members of management;

•

changes in economic and industry conditions;

•

reliance on third parties to provide services critical to our operations;

•

potential dilution of existing stockholders if we raise capital by issuing additional capital stock;

•

availability of appropriate prospective acquisitions or investment opportunities;

•

significant costs and obligations as a result of being a public company;

•

continued positive relationships with our customers;

•

deterioration in the collectability of our accounts;

•

major man-made or natural disasters;

•

compliance with applicable laws and regulations and cost of potential legal actions such as litigation or investigations;

•

inadequacy of our insurance coverage and fluctuating insurance requirements and costs;

•

impact of a potential requirement to record asset impairment charges in the future;

•

failure of our information technology system or the breach of our network security;

•

impact on our disclosure of use the scaled disclosure option available to smaller reporting companies; and

•

volatility in the price of our common stock.

OVERVIEW

References to “we,” “us,” “our,” “Tri-Isthmus Group,” “FPCG” or the “Company” refer to First Physicians Capital Group, Inc. and its subsidiaries. We maintain our executive offices at 433 North Camden Drive, #810, Beverly Hills, California 90210. Our telephone number is +1 (310) 860-2501.

We invest in and provide financial and managerial services to healthcare facilities in non-urban markets. We promote quality medical care by offering improved access and breadth of services. We unlock the value of our investments by developing strong, long-term and mutually-beneficial relationships with our physicians and the communities they serve.

This Form 10-Q report covers the fiscal quarter ended June 30, 2013.

Information in this Form 10-Q is current as of March 28, 2014, unless otherwise specified.

STRATEGY

During the Fiscal Year Ended September 30, 2010, we shifted our strategy away from majority ownership in healthcare delivery companies to a focus on the provision of management, financial, and ancillary healthcare and IT services to the rural and community hospital market. We expect to maintain and/or acquire minority ownership in selected healthcare delivery companies that complement our management services and financing activities. We may also invest in, acquire or partner with other companies that provide similar services in our markets.

In pursuit of this reorganization, we undertook an initiative to divest ourselves of underperforming facilities and reduce or outsource administrative functions to better align cost structures and business volume. As a result of the initiative, during the Fiscal Year Ended September 30, 2011, we successfully divested ourselves of our majority owned hospitals, and obtained contracts to provide the healthcare management services to several hospital clients.

We currently have 4 operating subsidiaries which are First Physicians Business Solutions, LLC, First Physicians Resources, LLC, First Physicians Services, LLC and First Physicians Realty Group. First Physicians Business Solutions, LLC provides an array of management services to include hospital operations management, revenue cycle management, IT, finance and human resources. First Physicians Services provides ancillary service oversight and management solutions for lab, pharmacy, and emergency departments in rural hospital settings. First Physicians Resources, LLC provides medical and back office staffing solutions to our hospital clientele. First Physicians Realty Group is our real estate subsidiary that owns healthcare related properties and leases them to clients. We currently have contracts to provide financial and back office services to two hospital clients.

MATERIAL CHANGES IN RESULTS OF OPERATIONS

REVENUE

Net revenue from services was $4.8 million for the three month period ended June 30, 2013, compared to $4.3 million for the three month period ended June 30, 2012, representing an increase of $0.5 million. Net revenue from services was $14.4 million for the nine month period ended June 30, 2013, compared to $12.1 million for the nine month period ended June 30, 2012, representing an increase of $2.3 million. The increases for both periods were the result of an increase in the scope and price of services provided by the Company under the contracts to provide healthcare management the Company obtained in 2011.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses increased by $0.6 million, to $3.2 million in the three month period ended June 30, 2013 compared to $2.6 million in the three month period ended June 30, 2012. Selling, general and administrative expenses increased by $1.3 million, to $9.3 million in the nine month period ended June 30, 2013 compared to $8.0 million in the nine month period ended June 30, 2012. These increases were the result of the increased costs associated with the increase in scope of the contracts to provide healthcare services management. Amortization of stock-based compensation is included in selling, general and administrative expenses for the three and nine month periods ended June 30, 2013 and 2012.

INTEREST EXPENSE

Interest expense decreased $211,000 to $148,000 for the three month period ended June 30, 2013 as compared to $359,000 for the three month period ended June 30, 2012. Interest expense decreased $188,000 to $666,000 for the nine months ended June 30, 2013 from $854,000 for the nine months ended June 30, 2012. The decreases for the three and nine month periods ended June 30, 2013 and 2012 were primarily the result of a $4.8 decrease in long term debt due to payments on long term borrowings.

MATERIAL CHANGES IN FINANCIAL CONDITION — AT JUNE 30, 2013, COMPARED TO SEPTEMBER 30, 2012:

CASH AND CASH EQUIVALENTS

As of June 30, 2013, cash and cash equivalents totaled $0.2 million, a decrease of $1.2 million when compared with the $1.4 million on hand at September 30, 2012. This decrease of 85.7% was primarily the result of the $3.6 million cash payments on long term debt, offset by net cash provided by operating activities of $2.4 million.

ACCOUNTS RECEIVABLES

As of June 30, 2013, accounts receivable, net of allowances for uncollectible accounts totaled $12.6 million, an increase of $3.0 million from $9.6 million at September 30, 2012. This increase was primarily due to the increased billings generated from an increase in the scope and price of healthcare management services provided by the Company.

LONG-TERM DEBT

Long-term debt (including current maturities) decreased $3.6 million from September 30, 2012 to June 30, 2013. This decrease reflects the $3.6 million cash payments made on long term debt during the period.

LIQUIDITY AND CAPITAL RESOURCES

We have funded operations primarily through cash flows from operations and short term bridge financing. We estimate that based on current plans and assumptions, that our available cash and cash flows from operations will be sufficient to satisfy our cash requirements under our present operating expectations, without further financing, for the next 12 months.

As of June 30, 2013 we had a working capital of $6.9 million compared with working capital of $2.2 million at September 30, 2012. This increase in working capital of $4.7 was primarily a result of the $3.0 million increase in accounts receivable and the $3.3 million reduction in current maturities of long term debt, offset by a $1.2 million decrease in cash.

As of June 30, 2013 we had a stockholders’ deficit of $4.3 million, as compared to a stockholders’ deficit of $9.5 million as of September 30, 2012. The decrease in stockholders’ deficit was primarily a result of the $4.5 million in net income for the nine month period ended June 30, 2013.

During the nine month period ended June 30, 2013 there was $2.4 million cash provided by operating activities, compared to $0.8 million cash provided by operating activities for the nine month period ended June 30, 2012. This $1.6 million increase in cash provided by operations was primarily the result of the $1.5 million gain on retirement of note payable in 2012.

Cash used in financing activities totaled $3.6 million in the nine month period ended June 30, 2013 and was a result of cash payments on long term debt of $3.6 million. Cash provided by financing activities totaled $1.8 million in the nine month period ended June 30, 2012 and was provided by proceeds from notes payable of $2.1 million, offset by routine payments of $0.3 million.

Prior to the current fiscal year, we sustained operating losses since our inception and have an accumulated deficit of approximately $85.9 million as of June 30, 2013, as compared with an accumulated deficit of $90.5 million as of September 30, 2012. These losses have been funded principally through the issuance of preferred and common stock, the issuance of promissory notes and cash generated from operations.

We are not aware of any trends, demands, events or uncertainties that will result in a material change in our liquidity or capital resources, nor do we expect any changes in the cost of our capital resources or the mix and relative cost of our capital resources.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

Item 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures: As of the end of the period covered by this report an evaluation was carried out by our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our controls and procedures contained evidence of a material weakness as of the end of the fiscal quarter ended June 30, 2013.

(b) Changes in Internal Control Over Financial Reporting: There were no changes in our internal control over financial reporting during the fiscal quarter ended June 30, 2013 that had a material effect on our internal control over financial reporting.

PART II

OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

None.

Item 1A. RISK FACTORS

Because we are a “Smaller Reporting Company,” we are not required to disclose the information required by this item.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

None.

Item 5. OTHER INFORMATION

None.

Item 6. EXHIBITS

See Exhibit index following the Signatures page.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EXHIBIT INDEX


Exhibit No.		Description

2.1*		Membership Interest Purchase Agreement (filed as Exhibit 2.1 to the Form 8-K, as filed with the SEC on November 5, 2007)

3.1*		Certificate of Incorporation (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on November 14, 2000)

3.2*		Amended and Restated Bylaws dated October 25, 2002 (filed as Exhibit 3.2 to the Form 8-K, as filed with the SEC on October 28, 2002)

3.3*		Certificate of Designation of Rights and Preferences of Series 2-A Convertible Preferred Stock filed November 8, 2000 (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on November 14, 2000)

3.4*		Certificate of Designation of Rights and Preferences of Series 3-A Convertible Preferred Stock filed June 20, 2001 (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on July 2, 2001)

3.5*		Certificate of Designation of Rights and Preferences of Series 4-A Convertible Preferred Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on October 28, 2002)

3.6*		Certificate of Designation of Rights and Preferences of Series 5-A Convertible Preferred Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on July 21, 2005)

3.7*		Certificate of Amendment to the Certificate of Designation of Rights and Preferences Series 5-A Convertible Preferred Stock filed January 10, 2008 (filed as Exhibit B to the Form of Series 5-A Preferred Stock and Warrant Purchase Agreement, filed as Exhibit 10.52 herein)

3.8*		Certificate of Designation of Rights and Preferences of Series 6-A Convertible Preferred Stock filed April 2, 2008 (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on April 3, 2008)

3.9*		Certificate of Amendment to the Certificate of Designation of Rights and Preferences of Series 5-A Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit 4.2 to the Form 10-Q, as filed with the SEC on May 20, 2008)

3.10*		Certificate of Amendment to the Certificate of Designation of Rights and Preferences of Series 6-A Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit B to the Form of Series 6-A Preferred Stock and Warrant Purchase Agreement, filed as Exhibit 10.54 herein)

3.11*		Certificate of Designation of Rights and Preferences of Series 7-A Convertible Preferred Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on December 12, 2013)

4.1*		Certificate of Decrease of Shares Designated as Series 7-A Convertible Preferred Stock, dated and filed January 22, 2010 (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on January 28, 2010)

4.2*		Certificate of Decrease of Shares Designated as Series 1-A Convertible Preferred Stock (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on July 13, 2005)


Exhibit No.		Description

4.3*		Certificate of Decrease of Shares Designated as Series 2-A Convertible Preferred Stock (filed as Exhibit 4.2 to the Form 8-K, as filed with the SEC on July 13, 2005)

4.4*		Certificate of Decrease of Shares Designated as Series 3-A Convertible Preferred Stock (filed as Exhibit 4.3 to the Form 8-K, as filed with the SEC on July 13, 2005)

4.5*		Certificate of Decrease of Shares Designated as Series 4-A Convertible Preferred Stock (filed as Exhibit 4.4 to the Form 8-K, as filed with the SEC on July 13, 2005)

4.6*		Form of Warrant (filed as Exhibit 4.2 to Form 8-K, filed with the SEC on July 21, 2005)

4.7*		Form of Warrant (filed as Exhibit 4.2 to Form 8-K, filed with the SEC on August 23, 2005)

4.8*		Form of Warrant (filed as Exhibit 4.2 to Form 8-K, filed with the SEC on September 22, 2006)

4.9*		Form of Extension of Warrant, dated July 18, 2007 (filed as Exhibit 4.1 to Form 8-K as filed with the SEC on December 18, 2008)

31.1		Certification Pursuant to Rule 13a-14(d) promulgated under the Securities Exchange Act of 1934

32.1		Certification Pursuant to 18 U.S.C. 1350

101.INS**		XBRL Instance Document

101.SCH**		XBRL Taxonomy Extension Schema

101.CAL**		XBRL Taxonomy Extension Calculation Linkbase

101.DEF**		XBRL Taxonomy Extension Definition Linkbase

101.LAB**		XBRL Taxonomy Extension Label Linkbase

101.PRE**		XBRL Taxonomy Extension Presentation Linkbase

*	Previously filed with the SEC as indicated, and hereby incorporated herein by reference.

Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company